Federico Mingozzi

USPTO Granted Patents = 15 (Patent Applications = 7)

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 5 (Patent Applications = 15)

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 32(Granted Patents)

Location History:

Philadelphia, PA (US) (2015 - 2023)
Paris, FR (2018 - 2024)

Company Filing History:

The Children's Hospital of Philadelphia

patents

6 out of 1,743

Institut National De La Sante Et De La Recherche Medicale

patents

4. 5 out of 21

Université D'evry-Val-d'essonne

Association Institut De Myologie

International Centre for Genetic Engineering and Biotechnology

patents

9. 1 out of 135

Fondazione Istituto Italiano Di Tecnologia

where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...

15 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12171843 - Hybrid regulatory elements (2024-12-24),

2. 12037362 - Hybrid recombinant adeno-associated virus serotype between AAV9 and AAVrh74 with reduced liver tropism (2024-07-16),

3. 11559589 - Compositions and methods for detection and modulation of T cell mediated immune responses against viral vectors utilized for gene therapy (2023-01-24),

4. 11541131 - Treatment of glycogen storage disease III (2023-01-03),

5. 11427836 - Method for reducing the expression of NKCC1 in a subject (2022-08-30),

6. 11421211 - Acid-alpha glucosidase variants and uses thereof (2022-08-23),

7. 11408899 - AAV vector and assay for anti-AAV (adeno-associated virus) neutralizing antibodies (2022-08-09),

8. 11376321 - Method for removing anti-AAV antibodies from a blood-derived composition (2022-07-05),

9. 11339406 - Acid-alpha glucosidase variants and uses thereof (2022-05-24),

10. 11279950 - Composition and methods for highly efficient gene transfer using AAV capsid variants (2022-03-22),

11. 10640785 - Virus vectors for highly efficient transgene delivery (2020-05-05),

12. 10471132 - Treatment of hyperbilirubinemia (2019-11-12),

13. 10392632 - AAV8 vector with enhanced functional activity and methods of use thereof (2019-08-27),

14. 9909142 - Composition and methods for highly efficient gene transfer using AAV capsid variants (2018-03-06),

15. 9075044 - Compositions and methods for detection and modulation of T cell mediated immune responses against viral vectors utilized for gene therapy (2015-07-07),

Title: The Innovative Journey of Federico Mingozzi

Introduction

Federico Mingozzi is a distinguished inventor based in Paris, France. With a portfolio of 15 patents, he has made significant contributions to the field of gene therapy and biotechnology. His work reflects a deep understanding of molecular biology and innovative approaches to address complex genetic diseases.

Latest Patents

Among his latest patents, Federico has developed hybrid transcription regulatory elements, aimed at enhancing gene expression through the design of hybrid promoters. These innovative elements allow for the fusion of at least two transcription regulatory elements with different tissue selectivity, thereby enabling more precise and targeted gene expression. Another notable invention is a hybrid recombinant adeno-associated virus (AAV) serotype that integrates characteristics from AAV serotype 9 (AAV9) and AAV serotype 74 (AAVrh74). This hybrid capsid protein showcases a reduced liver tropism compared to its parent serotypes, making it particularly useful in gene therapy applications, especially for treating neuromuscular genetic diseases.

Career Highlights

Federico Mingozzi has had a robust career in the field, having worked for reputable organizations such as Genethon and The Children's Hospital of Philadelphia. His focus on developing innovative gene therapy solutions has positioned him as a key player in the biotechnology sector, pushing forward the boundaries of medical science with his inventive approaches.

Collaborations

Throughout his career, Federico has collaborated with esteemed colleagues, including Katherine A. High and Giuseppe Ronzitti. These collaborations have enriched his work and contributed to the successful development of groundbreaking therapies that aim to improve the lives of individuals with genetic disorders.

Conclusion

In conclusion, Federico Mingozzi's contributions to the field of gene therapy through his innovative inventions and extensive patent portfolio underscore his role as a leading inventor in the biotechnology landscape. His work continues to inspire advancements in medical science and offers hope for effective treatments for various genetic conditions.

This text is generated by artificial intelligence and may not be accurate.